Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H33BrN6O3 |
| Molecular Weight | 653.568 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=CC(\C=C\C(O)=O)=CC=C2N=C1C3(CCC3)NC(=O)C4=CC5=C(C=C4)C(C6CCCC6)=C(N5C)C7=NC=C(Br)C=N7
InChI
InChIKey=BMAIGAHXAJEULY-UKTHLTGXSA-N
InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+
Deleobuvir is a drug for the treatment of Hepatitis C, developed by Boehringer Ingelheim. Deleobuvir is a non-nucleoside HCV NS5B polymerase inhibitor that reversibly and noncovalently binds to the thumb pocket 1. It has shown rapid and strong antiviral activity when administered in combination with peginterferon-a2a and ribavirin. In 2014 Boehringer Ingelheim decided to halt further development of deleobuvir because preliminary analysis of phase 3 clinical trials indicated a low efficacy of the drug.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Deleobuvir
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL2403318
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
DTXSID40235516
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
SUB126286
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
DB14850
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
1221574-24-8
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
SUPERSEDED | |||
|
9656
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
56948249
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
863884-77-9
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
C166826
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
BC-02
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
100000151870
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY | |||
|
58BU988K90
Created by
admin on Sat Dec 16 01:32:31 GMT 2023 , Edited by admin on Sat Dec 16 01:32:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
